Evidence map›Paper›PMID 36803818›Full record

ReviewHandbook of clinical neurology2023

Role of rodent models in advancing precision medicine for Parkinson's disease.

Emily Simons, Sheila M Fleming

Open access · greenAbstract readReview
In one paragraph

Review in Handbook of clinical neurology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
10.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Emily SimonsDepartment of Pharmaceutical Sciences, Northeast Ohio Medical University, Rootstown, OH, United States.
Sheila M FlemingDepartment of Pharmaceutical Sciences, Northeast Ohio Medical University, Rootstown, OH, United States. Electronic address: sfleming1@neomed.edu.
Northeast Ohio Medical University · US

Funding

ATP13A2 and Susceptibility to NeurodegenerationR01ES031124 · NIEHS · NORTHEAST OHIO MEDICAL UNIVERSITY · PI FLEMING, SHEILA · 2020 to 2024
$1.7M
NIEHS NIH HHS R01 ES031124
6 · The paper itself

Abstract

With a current lack of disease-modifying treatments, an initiative toward implementing a precision medicine approach for treating Parkinson's disease (PD) has emerged. However, challenges remain in how to define and apply precision medicine in PD. To accomplish the goal of optimally targeted and timed treatment for each patient, preclinical research in a diverse population of rodent models will continue to be an essential part of the translational path to identify novel biomarkers for patient diagnosis and subgrouping, understand PD disease mechanisms, identify new therapeutic targets, and screen therapeutics prior to clinical testing. This review highlights the most common rodent models of PD and discusses how these models can contribute to defining and implementing precision medicine for the treatment of PD.

Indexed as

Parkinson Diseasealpha-SynucleinAnimalsDisease Models, AnimalHumansPrecision MedicineRodentiaalpha-SynucleinAnimal modelsNeurotoxic modelsParkinson's diseasePrecision medicineRodent modelsTransgenic modelsα-Synuclein

Identifiers

PMID36803818
PMCPMC10251252
OpenAlexW4321020916

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.